Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Adalimumab

Classification: A

Drug products: AMGEVITA, Hukyndra, Hulio, Humira, Humira®, Hyrimoz, Idacio, Imraldi

ATC code: L04AB04

Substances: adalimumab

Summary

Studies on TNF inhibitors in different indications have shown worse treatment response and a higher rate of treatment discontinuation in women. The causes of these discrepancies are unknown. The incidence of cutaneous adverse events during TNF inhibitor treatment is higher in women than in men.
Register data have shown that women with rheumatoid arthritis are initiated on TNF inhibitor treatment at a higher level of self-reported disease activity but at the same level of physician-reported disease activity.

Additional information

Pharmacokinetics and dosing

In a randomized, double-blind, dose-titration study involving patients (13 men, 47 women) with rheumatoid arthritis receiving either adalimumab (0.25, 0.5, 1, 3, or 5 mg/kg) or placebo, clearance across all doses of adalimumab was 30% higher in women (0.010 vs. 0.03 L/h, p<0.05). However, the difference appeared to be mainly due to differences in body weight (23%) between men and women. The number of men receiving adalimumab was small (10 men, 35 women) [1]. The original manufacturer report that no gender-related pharmacokinetic differences have been observed after correction for a patient’s body weight [2]. Pharmacokinetics shows no differences between men and women when corrected for bodyweight. However, in adults adalimumab is administrated as a fixed dose. No studies with a clinically relevant sex analysis regarding the dosing of adalimumab have been found.

Effects

Rheumatoid arthritisSeveral studies have shown that men have a better response to TNF inhibitors and greater chance to achieve remission in rheumatoid arthritis (RA). A large observational study involving RA patients (165 men, 840 women) found a relative risk of 1.51 for remission associated with male sex within the first 14.5 months of therapy with standard doses of TNF-inhibitors (infliximab, etanercept or adalimumab) in patients with rheumatoid arthritis [3]. Also, an open-label study involving patients with active RA treated with adalimumab 40 mg s.c. every other week (1246 men, 5227 women), showed that men had longer duration of remission (hazard ratio 1.28) [4]. A large observational study (593 men, 2032 women) evaluating the effectiveness of adalimumab 40 mg every other week in RA showed that men had a lower disease activity and higher self-reported functional capacity at 12 months of therapy [5]. A Swedish observational study (252 men, 446 women) showed that fewer women with RA receiving anti-rheumatic agents (mainly sulfasalazine or methotrexate) were in remission at follow-up at 2 and 5 years than men. Disease activity, assessed by the doctor, had decreased less in women than in men. However, women had a higher baseline disease activity [6]. Contrary to these findings, in another observational study of patients with established RA (353 men, 1212 women) patient’s sex did not predict the response to TNF-inhibitors (infliximab, etanercept or adalimumab) [7].

Psoriatic arthritisPoorer treatment response among women treated with TNF inhibitors have also been described in patients with psoriatic arthritis. A systematic literature review found eight studies that examined differences between men and women in treatment discontinuation of TNF inhibitors in psoriatic arthritis. A higher risk of treatment discontinuation for women was reported in the majority of the included studies (n=3950 patients, about 45% women) [8]. Furthermore, a British observational controlled study (280 men, 316 women) showed that women treated with TNF inhibitors had lower response and remission rates at 6 months (OR 0.51 and 0.34, respectively) than men [9]. A later observational study included patients (35 men, 40 women) that initiated TNF inhibitor treatment (etanercept, golimumab and adalimumab) and were followed prospectively. After twelve months, minimal disease activity was achieved in 61% of the patients. Male sex was associated with two to three times higher odds of achieving response, no difference was seen between the different TNF inhibitors [10]. In another, open-label uncontrolled study (221 men, 221 women), patients received adalimumab 40 mg every other week in addition to standard therapy for 12 weeks. Men had higher response rates (OR 2.24) [11].

Ankylosing spondylitisResponse to TNF inhibitors (infliximab, etanercept or adalimumab) in patients with ankylosing spondylitis has been evaluated in an observational study (152 men, 68 women). Men were more likely to have a better treatment response at 6 months of treatment (odds ratio 2.99) [12].

PsoriasisAn observational study on patients with psoriasis that initiated biologic treatment (etanercept, adalimumab or ustekinumab) examined factors associated with response. The study included 3079 patients with data on baseline and six-month disease activity, 1791 of these patients were started on adalimumab (1039 men, 752 women). Among all patients, female sex was associated with reduced odds of achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) (OR 0.78,). Chance of achieving PASI90 was lower for etanercept-treated compared to adalimumab-treated (OR 0.25). However, there was some evidence of a comparatively better response to etanercept for women, than men [13].

Adverse effects

Sex differences in adverse drug reactions to immune suppressive medication (infliximab, adalimumab, certolizumab) have been analyzed in a review of medical records (386 men, 457 women). For patients treated with adalimumab, there were no significant differences between men and women in experience of adverse drug reactions. The most frequent adverse drug reaction to infliximab and adalimumab was allergic reactions, with a higher rate in women than men. No other sex-specific adverse drug reactions to TNF inhibitors were observed. As a result of adverse drug reactions, a higher proportion of women than men treated with TNFα-inhibitor stopped the treatment (19% vs. 9%). Also, a higher proportion of women than men switched to another TNF inhibitors (15% vs. 6%) [14].The risk of cutaneous adverse events was examined in an observational study that included 5 437 arthritis patients treated with TNF inhibitors (480 men, 848 women with adalimumab). Female sex was associated with a higher risk of cutaneous adverse events (incidence rate ratio 1.49) among all TNF inhibitor treated patients [15]. A similar observational study examined the incidence of cutaneous adverse events among TNF inhibitor-treated patients with chronic inflammatory arthritis (92 men, 165 women). After five years of follow-up, 71 (27.6%) patients experienced some type of adverse event involving the skin. Female sex was strongly linked to risk of cutaneous adverse events (OR 2.84) [16]. Another observational study examined drug discontinuation in biologics-treated psoriasis (etanercept, adalimumab or ustekinumab). The study included 226 men and 145 women and found that female sex predicted drug discontinuation due to adverse events in adalimumab (HR 2.91), as well as in etanercept and ustekinumab [17].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

A register-based study (2204 men, 7098 women) examined differences in disease characteristics at initiation of TNF inhibitors (etanercept, adalimumab and infliximab) between men and women. In women with rheumatoid arthritis, TNF inhibitor therapy was initiated at a higher level of patient reported disease activity than men. Except for slightly higher levels of c-reactive protein among men, physician-reported disease activity did not differ between the sexes [18]. A subsequent study (402 men, 1510 women) confirmed these results, however some of the patients were included in both studies [19].

Several studies have shown that the delay to initiation of therapy for patients with rheumatoid arthritis is similar for men and women and that no differences in the proportion of men and women receiving biologic agents have been found [20,21].

Adherence to TNF inhibitors (etanercept, infliximab, adalimumab) in rheumatoid arthritis and Crohn’s disease was examined in a systematic review. Although there were some important differences, adherence was consistently lower in women [22]. Another systematic review of adherence, showed that female sex was a predictor of low adherence to TNF inhibitor therapy in inflammatory bowel disease [23]. In contrast to his, male sex has been shown to be a predictor of discontinuation of TNFα-inhibitor treatment (adalimumab, etanercept, infliximab) in Korean patients with ankylosing spondylitis (HR 0.327) [24].

Female sex was associated with development of anti-drug antibodies against adalimumab (n=24) or infliximab (n=) in a clinical study [25].

Updated: 2022-11-28

Date of litterature search: 2022-10-07

References

  1. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700-21. PubMed
  2. Humira (adalimumab). DailyMed [www]. US National Library of Medicine. [updated 2014-12-01, cited 2015-06-15]. länk
  3. Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8:431-7. PubMed
  4. Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Sáez I, Unnebrink K, Kary S et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum. 2008;59:32-41. PubMed
  5. Kleinert S, Tony HP, Krause A, Feuchtenberger M, Wassenberg S, Richter C et al. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int. 2012;32:2759-67. PubMed
  6. Forslind K, Hafström I, Ahlmén M, Svensson B, BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis?. Ann Rheum Dis. 2007;66:46-52. PubMed
  7. Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:495-9. PubMed
  8. Generali E, Sciré CA, Cantarini L, Selmi C. Sex Differences in the Treatment of Psoriatic Arthritis: A Systematic Literature Review. Isr Med Assoc J. 2016;18:203-8. PubMed
  9. Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49:697-705. PubMed
  10. Perrotta FM, Marchesoni A, Lubrano E. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs. J Rheumatol. 2016;43(2):350-5. PubMed
  11. Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69:394-9. PubMed
  12. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94. PubMed
  13. Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069-1076. PubMed
  14. Zelinkova Z, Bultman E, Vogelaar L, Bouziane C, Kuipers EJ, van der Woude CJ. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J Gastroenterol. 2012;18:6967-73. PubMed
  15. Hernández MV, Sanmartí R, Cañete JD, Descalzo MA, Alsina M, Carmona L et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013;65:2024-31. PubMed
  16. Machado NP, Reis Neto ET, Soares MR, Freitas DS, Porro A, Ciconelli RM et al. The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis. Clinics (Sao Paulo). 2013;68:1189-96. PubMed
  17. Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175(2):340-7. PubMed
  18. Arkema EV, Neovius M, Joelsson JK, Simard JF, van Vollenhoven RF. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study. Ann Rheum Dis. 2012;71:1203-6. PubMed
  19. Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 2012;10:82. PubMed
  20. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11:R7. PubMed
  21. DeWitt EM, Lin L, Glick HA, Anstrom KJ, Schulman KA, Reed SD. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther. 2009;31:1871-80; discussion 1858. PubMed
  22. Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013;19:4344-50. PubMed
  23. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19:1528-33. PubMed
  24. Kang JH, Park DJ, Lee JW, Lee KE, Wen L, Kim TJ et al. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci. 2014;29:1205-11. PubMed
  25. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429-35. PubMed
  26. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Diana Rydberg, Carl-Olav Stiller

Approved by: Karin Schenck-Gustafsson